PHARMACEUTICAL RESEARCH AND MANUFACTURERS ASSOCIATION OF AMERICA PAC | PubSys CalAccessCommittee header
PHARMACEUTICAL RESEARCH AND MANUFACTURERS ASSOCIATION OF AMERICA PAC
Active cycles
2005-20062007-20082009-20102011-20122013-20142015-20162017-20182019-20202021-20222023-20242025-2026
Panel 2 • Finance overview
Committee finance snapshot
Scope: 2025-2026 cycle
- Raised
- $509,600Dated receipts + reported unitemized intervals
- Spent
- $535,300
- Net activity
- -$25,700
Receipt coverage evidence (82 components)
- Filing 3024177, amendment 0, F497P2: Receipt date 2025-02-24; $2,500.00; s497_not_received
- Filing 3123912, amendment 0, F497P2: Receipt date 2026-03-04; $2,500.00; s497_not_received
- Filing 3123912, amendment 0, F497P2: Receipt date 2026-03-04; $1,100.00; s497_not_received
- Filing 3123912, amendment 0, F497P2: Receipt date 2026-03-04; $2,000.00; s497_not_received
- Filing 3123912, amendment 0, F497P2: Receipt date 2026-03-04; $1,900.00; s497_not_received
- Filing 3123912, amendment 0, F497P2: Receipt date 2026-03-04; $3,500.00; s497_not_received
- Filing 3123912, amendment 0, F497P2: Receipt date 2026-03-04; $2,400.00; s497_not_received
- Filing 3127526, amendment 0, F497P2: Receipt date 2026-03-19; $3,000.00; s497_not_received
- Filing 3127526, amendment 0, F497P2: Receipt date 2026-03-19; $2,900.00; s497_not_received
- Filing 3127526, amendment 0, F497P2: Receipt date 2026-03-19; $5,900.00; s497_not_received
- Filing 3132810, amendment 0, F497P2: Receipt date 2026-04-10; $2,500.00; s497_not_received
- Filing 3132810, amendment 0, F497P2: Receipt date 2026-04-10; $1,900.00; s497_not_received
- Filing 3132810, amendment 0, F497P2: Receipt date 2026-04-10; $2,900.00; s497_not_received
Panel 3 • Money structure snapshot
Money structure snapshot
$5,000+ is the largest bucket at 100% of dated attributable receipts.
Dominant category: Operations at 100% of spending.
Funding distribution
$5,000+
Count: 52
Share: 100%
Amount: $509,600
| Contribution bucket | Count | Amount | Share of dated receipts |
|---|
| $5,000+ |
Panel 5 • Financial evidence
Filings workspace
Filing history and transaction-level evidence moved to a dedicated page.
Open filings pageLarge-donor funded, Non-media-led spender, Active in 2025-2026 cycle.
Money over time
Dated receipts only; unitemized reporting intervals are not allocated to dates.
ContributionsExpenditures
Jan 2025Jul 2025Feb 2026Sep 2026
Spending categories
Operations
Amount: $535,300
Share: 100%
| Category | Amount | Share of spent |
|---|
| Operations | $535,300 | 100% |
Panel 4 • Top donors
Top donors
| Donor | Total | Share* | Count | Last |
|---|
| AMGEN, INC. | $19,600 | 3.8% | 2 | Feb 18, 2026 |
| BAYER US, LLC(DEVON ANDERSON) | $19,600 | 3.8% | 2 | Feb 18, 2026 |
| BIOGEN INC. | $19,600 | 3.8% | 2 | Aug 4, 2026 |
| BRISTOL MYERS SQUIBB COMPANY | $19,600 | 3.8% | 2 | May 7, 2026 |
| EISAI, INC | $19,600 | 3.8% | 2 | Feb 18, 2026 |
| ELI LILLY AND COMPANY | $19,600 | 3.8% | 2 | May 7, 2026 |
| GENENTECH, INC. | $19,600 | 3.8% | 2 | May 7, 2026 |
| GENMAB | $19,600 | 3.8% | 2 | Mar 17, 2026 |
| GILEAD SCIENCES INC. | $19,600 | 3.8% | 2 | May 7, 2026 |
| JOHNSON & JOHNSON | $19,600 | 3.8% | 2 | Mar 17, 2026 |
| NEUROCRINE BIOSCIENCES | $19,600 | 3.8% | 2 | May 7, 2026 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $19,600 | 3.8% | 2 | May 7, 2026 |
| NOVO NORDISK, INC. | $19,600 | 3.8% | 2 | May 7, 2026 |
| OTSUKA AMERICA PHARMACEUTICAL, INC. | $19,600 | 3.8% | 2 | Feb 18, 2026 |
| PFIZER INC. | $19,600 | 3.8% | 2 | May 7, 2026 |
| PHARMACEUTICAL RESEARCH & MANUFACTURERS ASSN OF AMERICA | $19,600 | 3.8% | 2 | Apr 27, 2026 |
| SANOFI-AVENTIS | $19,600 | 3.8% | 2 | Mar 17, 2026 |
| UCB, INC. | $19,600 | 3.8% | 2 | Mar 17, 2026 |
| ALKERMES, INC. | $9,800 | 1.9% | 1 | Apr 14, 2025 |
| ASTRAZENECA PHARMACEUTICALS | $9,800 | 1.9% | 1 | Mar 17, 2026 |
| BOEHRINGER INGELHEIM PHARMACEUTICALS, INC USA | $9,800 | 1.9% | 1 | Feb 18, 2026 |
| BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | $9,800 | 1.9% | 1 | Apr 14, 2025 |
| CSL BEHRING | $9,800 | 1.9% | 1 | May 12, 2025 |
| GLAXOSMITHKLINE (GSK) | $9,800 | 1.9% | 1 | Mar 17, 2026 |
| GSK | $9,800 | 1.9% | 1 | May 12, 2025 |
* Share is percent of committee total raised in the selected scope. Page rows are a subset and typically do not sum to 100%.